Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis

Y. Levy, Y. Uziel, G. G. Zandman, H. Amital, Y. Sherer, P. Langevitz, B. Goldman, Y. Shoenfeld

Research output: Contribution to journalArticlepeer-review

77 Scopus citations


Background: Peripheral neuropathy is a prominent feature of the systemic and secondary vasculitides. Usually, it is responsive to corticosteroids, but in certain cases it may be resistant to corticosteroid or immunosuppressive treatment, or both. Objective: To present patients who exhibited various inflammatory diseases accompanied with vasculitic peripheral neuropathies for which intravenous immunoglobulin (IVIg) was used for treatment. Methods: Six patients with Sjögren's syndrome, systemic lupus erythematosus (SLE), vaccination induced vasculitis, Churg-Strauss vasculitis, mixed cryoglobulinaemia associated with hepatitis C infection, or sarcoidosis were included. All developed vasculitic peripheral neuropathy, and were treated with high dose IVIg (2 g/kg body weight). The patients were followed up for 1-5 years after this treatment. Results: In four patients (Sjögren's syndrome, Churg-Strauss vasculitis, SLE, and vaccination induced vasculitis) the neuropathy resolved after IVIg treatment. Conclusion: IVIg may be beneficial in cases of resistant vasculitic peripheral neuropathy. IVIg should probably be considered as a sole or adjuvant treatment for patients with contraindications to conventional treatment, or alternatively, for patients in whom conventional treatment has failed.

Original languageEnglish
Pages (from-to)1221-1223
Number of pages3
JournalAnnals of the Rheumatic Diseases
Issue number12
StatePublished - 1 Dec 2003
Externally publishedYes


Dive into the research topics of 'Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis'. Together they form a unique fingerprint.

Cite this